SH3 domain
SRC homology 3 domain is a protein module that binds to proline-rich sequences.
SH2 domain
SRC homology 2 domain is a protein module that binds to tyrosine phosphorylated sites in a sequence-specific context.
SH1 domain
SRC homology 1 domain refers to the tyrosine kinase domain, which was first identified in the SRC kinase.
Focal adhesions
Sites where integrins and proteoglycan-mediated adhesions connect to the actin cytoskeleton.
Adherens junctions
Intercellular adhesion structures that tightly seal the lateral spaces between cells in simple epithelia. They contain the intercellular adhesion molecule E-cadherin, as well as β-catenin and α-catenin. and regression 27, 28 . Functional overlap by ABL1 and ABL2 kinases is supported by the embryonic lethality of Abl1 −/− Abl2 −/− mice 27 .
Structure and regulation of ABL enzymatic activity.
ABL1 and ABL2 function redundantly in some cellu lar contexts, but also have unique roles, owing to dis tinct and conserved sequences and structural domains (FIG. 1) . ABL1 and ABL2 share aminoterminal regu latory and catalytic domains that are over 90% iden tical and that include the SRC homology 3 domain (SH3 domain), the SH2 domain and the SH1 domain (tyro sine kinase) (FIG. 1a) . The carboxyl terminus of both ABL kinases contains a conserved filamentous (F)actinbinding domain 29, 30 (and reviewed in REF. 6) (FIG. 1a) . ABL1 con tains a globular (G)actinbinding domain upstream of the Factinbinding domain, and ABL2 has a second internal Factinbinding domain that is characterized by an I/LWEQ motif, which is required to promote the formation of Factinrich structures at the cell periphery 30 . The ABL kinases share conserved PXXP motifs that mediate binding to SH3 domaincontaining proteins. Consistent with its nuclear and cytoplasmic localization, ABL1 has three nuclear localization signal (NLS) motifs and one nuclear export signal (NES) in its C terminus. By contrast, ABL2, which lacks the NLS motifs, primarily localizes to the cytoplasm and pref erentially accumulates at Factinrich sites in the cell periphery, focal adhesions, adherens junctions, invadopodia and phagocytic cups [31] [32] [33] [34] . Multiple isoforms of ABL1 and ABL2 have been detected; alternative splicing of the first exons results in isoforms with distinct Nterminal sequences (FIG. 1a) . The 1b isoforms of both ABL kinases contain an Nterminal glycine that is myristoylated, and the 1a variants lack this site and the corresponding modification.
The catalytic activities of the ABL kinases are tightly regulated by intermolecular and intramolecular inter actions and posttranslational modifications (FIG. 1b) . This topic has been extensively reviewed and thus is only briefly discussed here 5, 6, 35 . Among the promi nent intramolecular interactions that are required for auto inhibition are those involving the SH3 and SH2 domains 35 (FIG. 1b) . The SH3 domain binds to the polyprolinecontaining linker sequence that connects the SH2 and the kinase domains, and the SH2 domain interacts with the Cterminal lobe of the kinase domain (SH1), forming an SH3-SH2-SH1 clamp struc ture 35 . Autoinhibition is also mediated by the binding of the myristoylated residue in the ABL N terminus to a hydrophobic pocket within the Clobe of the kinase domain 36 . This interaction stabilizes the autoinhibited conformation of the myristoylated 1b isoform of the ABL kinase (FIG. 1b) . Inhibitory intramolecular interactions that stabilize the 1a isoform of ABL are poorly under stood and may involve binding to lipid residues in trans. In this regard, both ABL1 and ABL2 are inhibited by the lipid phosphatidylinositol4,5bisphosphate (PIP2; also known as PtdIns(4,5)P 2 ), and experimentally decreasing PIP2 levels in the cell stimulates ABL kinase activity 37 . ABL activity can be negatively or positively regulated by intermolecular interactions with distinct binding partners. In general, intermolecular interactions that disrupt auto inhibitory interactions and that stabilize the active (open) conformation of the ABL kinases promote increased enzymatic activity. For example, the catalytic efficiency of the ABL kinases can be enhanced by inter actions with adaptor proteins such as Ras and Rab interactor 1 (RIN1), which interacts with both the ABL SH3 and the SH2 domains 38 . Intermolecular interactions that stabi lize the inactive conformation of the ABL kinases inhibit enzymatic activity and downstream signalling. Among the proteins reported to negatively regulate ABL kinase activ ity are peroxiredoxin 1 (PRDX1; also known as PAG), the tumour suppressor protein FUS1 (also known as TUSC2) and the phosphataseinteracting adaptor protein PSTPIP1 (REFS 5, 11, 39, 40) .
The enzymatic activity of the ABL kinases is also regulated by tyrosine phosphorylation. Among the tyro sine residues phosphorylated on ABL1 are Y412 in the activation loop (corresponds to Y439 in ABL2) and Y245 in the SH2kinase domain linker (corresponds to Y272 in ABL2). Phosphorylation of these tyrosines stabilizes the active conformation of the ABL kinases, and can occur by transphosphorylation between ABL proteins or may be mediated by SRC family kinases 41 . The stability of ABL kinases can be modulated by tyrosine phosphorylation. Phosphorylation of ABL1 on Y245 and Y412 decreases protein stability through ubiquitylation and subsequent degradation by the 26S proteasome machinery 42 .
Key points
• ABL1 was first discovered more than 30 years ago as the oncogene in the Abelson murine leukaemia virus and was later identified as an oncogene that is associated with chromosome translocations in human leukaemias. Recently, activation of ABL1 and ABL2 has been detected in solid tumours.
• Activation of ABL kinases in solid tumours is driven by enhanced expression (amplification or increased mRNA levels) and/or by increased enzymatic activity downstream of hyperactive receptor tyrosine kinases, SRC, chemokine receptors, oxidative stress, assembly of activating protein complexes and inactivation of negative regulatory proteins.
• Disruption of cell polarity occurs early during tumorigenesis. Activation of ABL kinases results in dramatic inversion of epithelial apical-basal polarity by disrupting β1 integrin signalling and laminin assembly. Thus, activated ABL kinases may regulate early steps of tumour initiation.
• ABL kinases regulate the function of invadopodia, actin-rich structures that remodel the extracellular matrix during cancer cell invasion. ABL kinases are required for cancer cell invasion by regulating invadopodia components and the expression of genes that promote invasion and metastasis.
• ABL1 and ABL2 regulate overlapping and distinct cellular processes in various cell types and may differentially contribute to tumour progression. Future studies are required to evaluate unique roles for ABL kinases not only in selected solid tumours but also in cells in the tumour microenvironment.
• Treatment of BCR-ABL1-positive leukaemias with imatinib has emerged as the best example of the successful use of tyrosine kinase inhibitor (TKI)-targeted therapy. However, use of imatinib and related drugs is inadequate for the treatment of unselected solid tumours. The identification of new allosteric inhibitors with greater specificity against ABL kinases will allow for the evaluation of the contribution of ABL kinases for the treatment of solid tumours with hyperactive ABL kinases.
• ABL kinases are activated during acquired resistance to chemotherapy, and ABL1 inhibition can sensitize cancer cells to cytotoxic chemotherapies and targeted TKI therapies. 
Phagocytic cups
Actin-rich membrane invagination that closes to form phagosomes during phagocytosis.
Activation loop
Conserved regulatory motif that extends into the active kinase domain and that is phosphorylated in the active conformation of the kinase; the activation loop serves as a binding platform for the peptide substrate to be phosphorylated. Alternative splicing of ABL1 and ABL2 produces several isoforms, including the 1a isoforms (as shown by the straight line) and the 1b isoforms (jagged line); the 1b isoforms are targeted for amino-terminal myristoylation 153 . The ABL N termini are comprised of the SRC homology 3 (SH3), SH2 and SH1 (tyrosine kinase) domains. The ABL carboxyl termini contain a conserved filamentous (F)-actin-binding domain (BD). ABL1 has a globular (G)-actin-binding domain and a DNA-binding domain, whereas ABL2 has a second internal F-actin-binding domain and a microtubule (MT)-binding domain. ABL1 has three nuclear localization signal (NLS) motifs and one nuclear export signal (NES) in its C terminus. Both ABL1 and ABL2 have conserved PXXP motifs to mediate protein-protein interactions. Phosphorylation (P) of ABL1 at Y412 within the activation loop (Y439 in ABL2) and Y245 in the SH2-kinase domain linker (Y272 in ABL2) stabilizes the active conformation. b | Representation of auto-inhibited (closed) and active (open) ABL kinases to depict the role of intramolecular interactions in the regulation of ABL kinase activity. The SH3 domain binds to the linker sequence connecting the SH2 and the kinase domains, and the SH2 domain interacts with C-terminal lobe of the kinase (SH1) domain forming an SH3-SH2 clamp structure. The myristoylated residue in the N terminus of the 1b ABL isoforms binds to a hydrophobic pocket within the C-lobe of the kinase domain, stabilizing the auto-inhibited conformation. The configuration and interactions of the ABL C-terminal sequences are not included in the model. Dashed line represents ABL N-terminal sequences upstream of the SH3 domain that fold over to promote binding of the myristoyl group to a pocket in the C-lobe of the kinase domain. c | Specificity of selected ABL tyrosine kinase inhibitors (TKIs) is shown: imatinib (Gleevec; Novartis), nilotinib (Tasigna; Novartis), dasatinib (Sprycel; Bristol-Myers Squibb), ponatinib (Iclusig; Ariad Pharmaceuticals) and GNF-2 and GNF-5 (allosteric inhibitors in preclinical studies). The kinase selectivity profiles for imatinib, nilotinib and dasatinib were generated on the basis of the binding of cellular kinases to inhibitors immobilized on solid support matrices (previously reviewed in REF. 75 ). Ponatinib-sensitive kinases were identified by in vitro kinase assays; shown are targets with half-maximal inhibitory concentration (IC 50 ) values of less than 20 nM 152 . Kinases sensitive to GNF-2 and GNF-5 were identified by in vitro kinase assays 56, 154, 155 . ACVR2B, activin receptor type 2B; BLK, B lymphoid tyrosine kinase; CSF1R, macrophage colony-stimulating factor 1 receptor; EGFR, epidermal growth factor receptor; EPHRs, ephrin receptors; FGFR, fibroblast growth factor receptor; FRK, fyn-related kinase; GAK, cyclin-G-associated kinase; GCK, glucokinase; ILK, integrin-linked protein kinase; LIMK, LIM domain kinase; NLK, nemo-like kinase; NQO2, NAD(P)H dehydrogenase, quinone 2; PDGFR, platelet-derived growth factor receptor; PTK, protein tyrosine kinase; RIPK2, receptor-interacting serine/threonine-protein kinase 2; SIK, salt-inducible kinase; SLK, STE20-like serine/threonine-protein kinase; TAOK3, TAO kinase 3; TESK2, dual specificity testis-specific protein kinase 2; VEGFR, vascular endothelial growth factor receptor.
ABL activation in leukaemias
Oncogenic activation of the ABL kinases occurs in Philadelphiapositive (Ph + ) human leukaemias as a conse quence of the t(9;22)(q34;q11) chromosome trans location that generates BCR-ABL1 fusion proteins with constitu tive tyrosine kinase activity. Three different BCR-ABL1 proteins have been identified that differ in the number of BCR sequences retained in the fusion protein, and which are associated with distinct types of leukaemia: P210 BCR-ABL1 is the molecular hallmark of CML (reviewed in REF. 43 ); P185 BCR-ABL1 is present in 20-30% of adult and in 3-5% of childhood B cell acute lympho cytic leukaemia (BALL) 44, 45 ; and P230 BCR-ABL1 has been detected in neutrophilic CML 46 , as well as in rare cases of CML 47 . The preferential association of the various BCR-ABL1 forms with distinct leukaemias is not abso lute, as some cases of Ph + BALL express P210 BCR-ABL1 (REF. 43 ). The role of the BCR-ABL1 fusion proteins in the initiation and the progression of leukaemia has been extensively covered in previous reviews and is not discussed here 48, 49 . Oncogenic activation of ABL1 in the BCR-ABL1 chimeric proteins is dependent on the presence of an Nterminal coiledcoil (CC) oligomeri zation domain in BCR 50, 51 . Multiple signalling pathways have been identified that function to mediate the onco genic activity of BCR-ABL1, including the RAS, nuclear factorκB (NFκB), PI3K-AKT, JUN, βcatenin and sig nal transducer and activator of transcription 3 (STAT3) signalling pathways 48, 52 . Recent proteomic approaches have identified proximal signalling networks linked to BCR-ABL1 (REF. 53 ). Interestingly, some of the adaptor proteins and signalling enzymes identified as compo nents of the BCR-ABL1 network have been functionally linked to the ABL1 and/or ABL2 kinases 5, 54 . Inhibition of P210 BCR-ABL1 with smallmolecule chemical inhibitors in chronic phase CML is perhaps the most successful example of molecularly targeted therapy to date 55 
. The BCR-ABL1 inhibitor imatinib is an effective firstline therapy for the majority of patients diagnosed with chronic phase CML, but it is much less effective when used to treat patients who have blast crisis CML or Ph + BALL 43 . Inhibitors of the ABL kinases are classified into three main classes on the basis of their mechanism of action: type 1 inhibitors target the active conformation of the kinase domain (dasatinib and bosutinib), whereas type 2 inhibitors stabilize the inactive conformation of the kinase domain, prevent ing its activation (imatinib, nilotinib and ponatinib). The third category of inhibitors includes allosteric inhibitors, which do not compete for ATP binding but which rather bind to regulatory domains to inhibit kinase activity (FIG 1b,c) . Among these are GNF2 and GNF5, which target the myristoylbinding pocket in the Clobe of the ABL kinase domain 56 . In contrast to the ATPcompetitive inhibitors that target multiple kinases, the allosteric inhibitors are highly selective for the ABL kinases (FIG. 1c) . These allosteric inhibitors decrease BCR-ABL1 enzymatic activity and inhibit BCR-ABL1driven leukaemogenesis in mice 56 , thus underscoring the importance of intramolecular auto inhibitory mechanisms that regulate the kinase activity of the oncogenic fusion protein.
ABL1 has been identified as a fusion partner with an increasing number of genes in rare chromosome trans locations in T cell acute lymphoblastic leukaemia (TALL), BALL and other leukaemias (FIG. 2) . In addition to BCR, at least eight other ABL1 fusion partners have been identified to date, including nucleoporin 214kDa (NUP214), ETS variant 6 (ETV6; also known as TEL), echinoderm microtubuleassociated proteinlike 1 (EML1), zinc finger, MIZtype containing 1 (ZMIZ1), RCSD1, the splicing factor SFPQ, forkhead box P1 (FOXP1) and sorting nexin 2 (SNX2) [57] [58] [59] (FIG. 2) . The BCR-ABL1 and ETV6-ABL1 fusions are associated with several types of leukaemia, including CML, BALL, TALL and acute myeloid leukaemia (AML), and these ABL1 translocations may occur in haematopoietic pluri potent or committed stem cells (reviewed in REFS 58, 60) . By contrast, the NUP214-ABL1 and EML1-ABL1 fusions are primarily linked to TALL, and the RCSD1-ABL1, SFPQ-ABL1, ZMIZ1-ABL1, FOXP1-ABL1 and SNX2-ABL1 fusions are associated with BALL. In gen eral, the fusion partners encode proteins that contain coiledcoil or helix-loop-helix motifs that promote the oligomerization of the resulting chimeric ABL kinases. However, the NUP214-ABL1 fusion, which is present in about 6% of TALL cases, requires localization to the nuclear pore complex rather than oligomerization for enhanced transforming activity 61 . Although the major ity of chimeric fusions involve ABL1, the ABL2 gene was identified as a partner of ETV6 in rare cases of TALL and AML 60 (FIG. 2) . In general, the distinct partners that are fused to the N terminus of the ABL kinases pro mote enhanced kinase and transforming activities by disrupting inhibitory intramolecular interactions, pro viding sequences that facilitate oligomerization, enhanc ing tyrosine phosphorylation and/or by recruiting the chim eric kinases to distinct subcellular sites and protein complexes. The effectiveness of the ABL TKIs for the treatment of leukaemias associated with the diverse ABL fusion partners other than BCR remains to be established.
Box 1 | ATP-competitive ABL kinase inhibitors
Imatinib (Gleevec; Novartis), was the first targeted ABL inhibitor developed and approved for the treatment of chronic myeloid leukaemia (CML). Treatment of CML and other Philadelphia-positive (Ph + ) leukaemias expressing BCR-ABL1 produced durable remissions in adults and children treated in the chronic phase 49, 150 . Remarkably, treatment of children with Ph + acute lymphocytic leukaemia (ALL) with imatinib plus chemotherapy has shown improved early event-free survival 151 . Although imatinib has proved an effective drug for patients with CML, up to one-third of patients with CML require alternative therapies 132 . The most common reason for imatinib resistance is the development of mutant forms of BCR-ABL1, including the T315I gatekeeper mutant, which prevent imatinib from docking in the ATP-binding pocket. Second-generation inhibitors such as nilotinib (Tasigna; Novartis), which inhibits ABL kinases at tenfold to 20-fold lower concentrations than imatinib, are used to treat imatinib-resistant disease 131 . Other second-generation inhibitors, including dasatinib (Sprycel; Bristol-Myers Squibb) and bosutinib (Bosulif; Pfizer), inhibit ABL kinases at even lower concentrations than nilotinib but, like nilotinib and imatinib, are ineffective against the BCR-ABL1 T315I mutant 131 . More recently, ponatinib (Iclusig; Ariad Pharmaceuticals) was shown to inhibit both wild-type and imatinib-resistant BCR-ABL1 mutants, including the T315I mutant, with similar potency. Similar to dasatinib and bosutinib, ponatinib has broad target specificity 152 (FIG. 1c) . Nature Reviews | Cancer 
ABL kinases in solid tumours
In contrast to the wellestablished role of BCR-ABL1 in CML, less is known about the role of the ABL kinases in solid tumours. Accumulating data support a role for ABL kinases in solid tumours characterized by enhanced expression and/or activation of these kinases. The Cancer Genome Atlas (TCGA) and other studies have shown that ABL1 and ABL2 are amplified and/or overexpressed in invasive breast carcinoma, ovarian serous cystadenocarcinoma, lung adenocarcinoma and lung squamous cell carcinoma [17] [18] [19] (TABLE 1) . Alterations in ABL1 or ABL2 are also found in skin cutaneous melanoma, bladder urothelial carcinoma, colorectal adenocarcinoma, rhabdoid tumours, as well as renal medullary and clear cell renal carcinoma 19, 20, 62 (see also the cBioPortal for Cancer Genomics website). Recent data generated from largescale sequencing projects have revealed that alterations (such as amplification, an increase in mRNA levels or somatic mutations) are more common in ABL2 than in ABL1, with observed ABL2 alterations in breast invasive carcinoma (18%), uterine endometrioid carcinoma (19%), ovarian serous cysta denocarcinoma (15%), lung adenocarcinoma (16%) and lung squamous cell carcinoma (15%) 17 (see also the cBioPortal for Cancer Genomics website) (TABLE 1) . Prevalent among these alterations is ABL2 amplification, which has been detected in invasive breast carcinomas (12%) 17 and in nonsmallcell lung adenocarcinomas (9%) 18 (see also the cBioPortal for Cancer Genomics website). These findings are consistent with earlier reports of increased ABL2 expression in advanced high grade colorectal, pancreatic, renal and gastric tumours, implicating an association between ABL2 activity and tumour progression 20, [63] [64] [65] . The prevalence of ABL2 . The ETV6-ABL2 fusion protein is present in rare cases of T-ALL and AML
60
. The nucleoporin 214kDa (NUP214)-ABL1 and echinoderm microtubule-associated protein-like 1 (EML1)-ABL1 fusions are primarily linked to T-ALL, and the RCSD1-ABL1, splicing factor, proline/glutamine-rich (SFPQ)-ABL1, zinc finger, MIZ-type-containing 1 (ZMIZ1)-ABL1, forkhead box P1 (FOXP1)-ABL1 and sorting nexin 2 (SNX2)-ABL1 fusions are associated with B-ALL 57, 59 . The coiled-coil (CC) and other motifs in the fusion partner promote oligomerization of the resulting chimeric ABL kinases. The BCR-ABL1, NUP214-ABL1, ETV6-ABL1, ETV6-ABL2, EML1-ABL1 and ZMIZ1-ABL1 fusion proteins retain the SH3, SH2 and kinase (SH1) domains of the ABL kinase. The RCSD1-ABL1, SFPQ-ABL1, FOXP1-ABL1 and SNX2-ABL1 fusions lack the SH3 but retain part of or the entire SH2 domain. The v-ABL1 oncoprotein fuses GAG sequences of Abelson murine leukaemia virus to sequences upstream of the ABL1 SH2 domain 57, 58 . The v-ABL1 oncoprotein induces murine lymphosarcoma and acute pre-B cell leukaemia 156, 157 . BD, binding domain; HELP, hydrophobic EMAP-like protein domain; MT, microtubule; NA, not applicable; RRM, RNA recognition motif.
ERBB receptors
Family of structurally related receptor tyrosine kinases of which there are four members, EGFR (also known as ERBB1), ERBB2 (also known as HER2), ERBB3 and ERBB4.
amplification and enhanced gene expression is compara ble to that reported for several kinases that have previously been implicated in invasive breast carcinoma 17 . Somatic mutations of ABL1 and ABL2 in solid tumours are rare but have been reported in certain solid tumours, including lung cancer and uterine corpus endometroid car cinoma [66] [67] [68] [69] (see also the cBioPortal for Cancer Genomics website). The role of these mutations in regulating ABL oncogenic activity remains to be determined.
In addition to genomic amplification and changes in ABL mRNA expression in tumours, increased ABL kinase activity has been reported in several cell lines derived from solid tumours. Quantitative proteomic analysis in cancer cells expressing the ERBB receptors showed that ABL1 was rapidly activated in response to epidermal growth factor (EGF) stimulation 7 . This is consistent with previous findings that showed that ABL kinases are activated downstream of the receptor tyrosine kinases (RTKs) plateletderived growth fac tor receptor (PDGFR) and EGF receptor (EGFR; also known as ERBB1) in fibroblasts 70 . Subsequent studies demonstrated that ABL kinases are tyrosine phosphory lated and are activated in breast, lung, colorectal, gastric and prostate cancer cells, as well as in melanoma [8] [9] [10] [11] [12] [13] [14] [15] [16] . Analysis of global tyrosine phosphorylation profiles of lung cancer cells showed higher levels of ABL tyrosine phosphorylation, but the identity of the upstream sig nals that promote tyrosine phosphorylation of the ABL kinases, and their role in the initiation and progression of lung tumours is mostly unknown [10] [11] [12] [13] . The mechanisms regulating ABL activation in solid tumours differ from the constitutive kinase activation that is observed in BCR-ABL1 + disease (TABLE 2) . In solid tumour cells, ABL activation has often been linked to stimulation by hyperactive RTKs and chemokine recep tors 8, 33 . Indeed, activation of ABL kinases in breast cancer cells has been shown to occur downstream of the EGFR, ERBB2 (also known as HER2) and insulinlike growth factor 1 receptor (IGF1R), as well as the chemokine receptor CXCR4 (REFS 8, 33, (71) (72) (73) . Activation of ABL1 in GTL16 gastric carcinoma cells and HepG2 hepato cellular carcinoma cells was induced by liganddependent activation of MET 15 , and ABL1 activation in HT29 colon cancer cells was stimulated by PDGF 9 . Enhanced ABL1 kinase activity in human anaplastic thyroid carcinoma cells was induced by the RET-PTC3 (also known as RET-NCOA4) fusion protein, a constitutively active form of the RET RTK 74 . Thus, the catalytic activity of the ABL kinases can be upregulated by ligand dependent and ligandindependent activation of RTKs. In addition to activation by upstream kinases, ABL kinases can also be activated through the inac tivation of negative regulatory networks, including interactions with inhibitory proteins. In this regard, activation of ABL1 in two lung adenocarcinoma cell lines correlated with the loss of FUS1 (REF. 11 ).
Regulation of proliferation and survival by ABL
The activation of ABL kinases in solid tumour types has been linked to alterations in cell growth and survival. Several studies have reported inhibitory effects of imatinib, nilotinib and related ABL TKIs (BOX 1) on cancer cell pro liferation and survival in vitro and in xenograft studies, but the cellular responses to these compounds cannot be solely attributed to inhibition of the ABL kinases, as these compounds have numerous kinase targets and some nonkinase targets 75, 76 (FIG. 1c) . Depletion of either ABL1 or ABL2 using specific small interfering RNAs in breast cancer cells that express increased levels of one or both proteins showed that both kinases were required for anchorageindependent growth 72 . Both ABL kinases were also required for maximal proliferation of melanoma cell lines 16 . By contrast, growth and survival under nutri ent deprivation required ABL2 but not ABL1 expression in some cancer cells (MDAMB435S and BT549) 72 . Additionally, depletion of ABL2 alone in nonsmallcell lung cancer lines decreased cell growth 77 , and ABL1 alone was required for survival and anchorageindependent growth of gastric and hepatocellular carcinoma cells 15 . Among the pathways mediating ABL1dependent prolif erative pathways are the RAC, p38 and ERK5 signalling pathways (reviewed in REF. 78 ). Thus, cancer cells express ing high levels of ABL1 and/or ABL2 can become reliant on one or both kinases for cell growth and viability. . ‡ mRNA z-score threshold = +/-2.0.
3D cultures
A system of growing cells in a three-dimensional environment, matrix or scaffold to more closely model physiological conditions.
Accumulating data show that a growing number of signalling networks (such as the transforming growth factorβ (TGFβ), WNT and Hippo pathways) exhibit contextdependent activities in solid tumours and can promote tumorigenesis or tumour suppression under different circumstances [79] [80] [81] . Although ABL kinases promote cell proliferation and survival in leukaemias and in some solid tumour cell lines, three reports have shown that ABL kinases suppress the growth of breast cancer xenografts [82] [83] [84] . Stimulation of the EPHB4 receptor with ephrin B2 in breast cancer cells decreased cell growth through an ABL-CRK pathway, and imatinib blocked the inhibitory effect of ephrin B2 on the growth of these breast cancer xenografts 82 . Further, expression of a constitutively active form of ABL1 in the 4T1 murine mammary tumour cell line enhanced the growthsuppressive effects of TGFβ in threedimensional cultures (3D cultures), and inhibited the growth of 4T1 tumour xenografts 83 . A recent report showed that knockdown of ABL2 in the MDAMB231 breast cancer cell line enhanced the growth of MDAMB231 xenograft tumours owing to increased cell proliferation 84 . ABL1 and ABL2 have overlapping functions during cell proliferation in some cell types, but the consequences of depleting both kinases on the growth of the MDAMB231 xenograft tumours was not reported in this study 84 . In contrast to the growthinhibitory role of ABL kinases in the 4T1 and MDAMB231 xenografts, depletion of both ABL1 and ABL2 in the MCF7 breast cancer cell line markedly impaired the growth of MCF7 xenograft tumours, sup porting a tumourpromoting function for ABL kinases in this cell line 85 . A role for ABL kinases in the growth of mammary tumours may depend on the cellular con text, the range of oncogenes and tumour suppressors expressed in the tumour, redundancy in the function of ABL1 and ABL2 kinases, and upstream signals that regulate tumour suppressive versus tumour promoting pathways in distinct cell lines.
ABL kinases regulate cellular stress responses ABL kinases can be activated in response to distinct types of cellular stress, including those mediated by reactive oxygen species (ROS) [86] [87] [88] [89] . Increased levels of ROS are a characteristic of many solid tumours 90, 91 and are also an inevitable byproduct of cellular metabolism. High levels of ROS can induce cell death, whereas lower chronic levels of ROS may induce inflammation, and can promote tumorigenesis and other disease states 92 . Oxidative stress results when the level of oxidants in the cells supersedes the antioxidant defence and may be induced by exogenous as well as endogenous sources 93 . Owing to increased cellular metabolism, cancer cells are vulnerable to oxidative stress, as the antioxidant defence system may be operating at its maximum threshold 94 . ABL kinase activation and signalling are differentially affected by ROS levels. ABL2 was reported to promote cell survival in response to low levels of oxidative stress, but high levels of oxidative stress correlated with ABL2 degradation and apoptosis 95, 96 . In this regard, increased tyrosine phosphorylation of ABL2 on Y439 induced by high ROS levels promoted ABL2 ubiquitylation and protein degradation 95 . By contrast, phosphorylation on Y261 enhanced ABL2 protein stability in response to low ROS levels 95 . ABL kinases can mediate antiproliferative and apoptotic responses induced by ROS and DNA dam age 86, 97, 98 . Whether ABL1 promotes or inhibits cell growth may depend on the status of p53 or the related p73 (REFS 99-103) . ABL1 was shown to enhance the 
Apical-basal polarity
Epithelial cells are polarized, with an apical membrane that faces the external environment or a lumen and is opposite the basolateral membrane, which functions in cell-cell interactions and contacts the basement membrane.
Planar cell polarity
The coordinated polarization of cells in the plane of the tissue.
proliferation of fibroblasts that lacked p53 under non stress conditions 99, 104 . However, in response to cellular stresses, including DNA damage, ABL1 induced growth arrest and/or apoptosis that was mediated by p53 or p73 (REF. 104 ). Interestingly, ABL1 can differentially modulate p53 activity and cellular responses through the alteration of MDM2, a regulator and transcriptional target of p53. Mechanistically, ABL1 protects p53 from the inhibitory effect of MDM2, by promoting MDM2 tyrosine phos phorylation, which restricts its interactions with p53, allowing for the accumulation of p53 and the promotion of apoptosis under stress conditions 104 . Recently, ABL1 was shown to be required for cell survival and activa tion of a p38 MAPK-p53-MDM2 pathway in response to ligand activation of the MET RTK in hepatocellular carcinoma cells 15 . Thus, ABL kinases can differentially disrupt the p53-MDM2 regulatory loop to suppress or promote cell growth and survival depending on the upstream signals that lead to ABL activation and the cellular context.
In addition to oxidative stress, growth factor depri vation was reported to activate ABL1 in mammary epi thelial cells by inducing binding to the MIG6 (also known as ERRFI1) adaptor and triggering p73dependent apoptosis 89 . Silencing ABL1 in primary mammary epi thelial cells (pMECs) in 3D cultures impaired lumen formation, which may be partly due to decreased cell death 89 . However, in comparison to wildtype pMECs, the ABL1depleted pMECs failed to reconstitute the mam mary gland after transplantation into the cleared mouse fat pads, suggesting impaired cell proliferation in the absence of ABL1 (REF. 89 ). It is likely that activation of ABL kinases by oxidative stress and/or reduced nutrient avail ability prevalent in many solid tumours may modulate tumour cell survival, invasion and metastasis 90, 91 . ABL family kinases regulate morphogenesis ABL in cell polarity. Disruption of cell polarity is an early event in the evolution of epithelial tumours 105 . A role for ABL kinases in the regulation of epithelial apical-basal polarity was first described in Drosophila melanogaster [106] [107] [108] . D. melanogaster Abl also regulates planar cell polarity during axis elongation by modulating the tyrosine phosphorylation and localization dynamics of βcatenin 109 . Recently, Abl was shown to be required for planar cell polarity in the D. melanogaster eye and wing by regulation of Frizzled-Dishevelled signal ling 110 . Furthermore, expression of activated ABL2, and to a lesser extent ABL1, induces a striking inversion of apical-basal polarity in epithelial cells that are grown in a 3D cell culture system in the presence of collagen 111 (FIG. 3a) . Inversion of apical-basal polarity by active ABL2 is mediated by at least two pathways, which include the disruption of β1 integrin localization and signalling downstream of the Rasrelated protein RAP1A, and impaired RAC1mediated laminin assembly 111 (FIG. 3b) .
Thus, ABL kinases may contribute to the loss of epithelial polarity at early stages of tumour development.
Spindle orientation is important for morphogenesis, asymmetric cell division and stem cell selfrenewal, pro cesses that are deregulated during tumorigenesis [112] [113] [114] [115] . Notably, a recent report showed that ABL1 regulates spin dle orientation in epithelial cells in culture and the mouse epidermis 116 . Loss of ABL1 induces spindle misorienta tion through the regulation of the polarity proteins LGN (also known as GPSM2) and nuclear mitotic apparatus protein 1 (NUMA1). Whether the ABL1induced changes in spindle orientation contribute to tumour progression remains to be determined. Interestingly, β1 integrin reg ulates apical-basal epithelial cell polarity and controls spindle orientation in embryonic mouse skin, and the Figure 3 | Active ABL kinases regulate epithelial cell polarity through β1 integrin. a | Epithelial cells expressing control vector or constitutively active forms of the ABL kinases (ABL1-PP or ABL2-PP, which have two proline to glutamate substitutions in the linker region between the kinase and SH2 domains that disrupt intramolecular inhibitory interactions with the SH3 domain) were grown in collagen gels and stained for the apical polarity marker gp135, the adherens junction marker E-cadherin and the nuclear DAPI stain. Active ABL2 and to a lesser extent ABL1 promote polarity inversion. All pictures were taken at ×40 magnification. Scale bar: 25 μm. Images are similar to those published in REF. 111 . b | Model for the inversion of epithelial cell polarity by active ABL kinases. Activation of ABL downstream of receptor tyrosine kinases (RTKs), chemokine receptors, oxidative stress and other signals leads to disruption of β1 integrin signalling and localization by regulation of the RAP1A GTPase via ABL2-mediated phosphorylation of CRK and the disruption of the CRK-C3G (RAPGEF1) complex. Active ABL2 also impairs RAC1-mediated laminin assembly in epithelial cysts 111 . Images in part a couretsy of R. Li, Duke University School of Medicine, USA. Nature Reviews | Cancer 
WAVE protein complex
Mediates the activation of the Arp2/3 complex at the leading edge of migrating cells.
localization of LGN and NUMA1 is disrupted in the epi dermis of β1 integrinknockout mice 117 . Because expres sion of activated ABL2 disrupts β1 integrin localization and signalling in epithelial cells 111 , an intriguing possibility is that activated ABL kinases might disrupt spindle orien tation indirectly through β1integrin, as well as directly through targeting LGN and NUMA1.
ABL in epithelial-to-mesenchymal transition. The pro gression of solid tumours involves dramatic changes in cell morphology, adhesion, motility and polarity that are dependent on cytoskeletal rearrangements. Epithelial tumours can activate dormant develop mental pathways that promote conversion from organized epithelial tis sue to isolated cells with mesenchymal morphology through the epithelialtomesenchymal transition (EMT) programme 118, 119 . EMT is characterized by the loss of cell polarity, disassembly of cell-cell junctions, acquisition of mesenchymal cell morphology and gene expression profiles, together with enhanced cell motil ity and invasion. Notably, these cellular processes are linked to signalling networks regulated by ABL family kinases. ABL1 is required for PDGFinduced EMT in colon cancer cells; this involves ABL1 phosphorylation of the p68 helicase (DDX5), which promotes βcatenin nuclear translocation 9 . Consequently, depletion and pharmacological inhibition of ABL kinases in colon and cervical cancer cells was shown to promote epithelial phenotypes in cells that had been induced to undergo EMT 9,120 . Recently, ABL1 was shown to be required for claudin 1induced EMT in human liver cells and hepato cellular carcinoma cell lines by regulating the activation of the RAS-RAF-ERK pathway 121 . ABL1 may have a contextdependent role during EMT, as pharma cological inhibition or silencing of ABL kinases in nor mal epithelial cells results in the dissolution of cell-cell junctions without inducing the expression of genes required for the EMT programme 32, 111 . Interestingly, alternative splicing promoted by EMT in breast cancer cells results in the formation of a spliced ABL2 isoform predominantly expressed in mesenchymal cells 122 . Roles for this ABL2 isoform specifically and for the ABL kinases in general during EMT in solid tumours are poorly defined and require further study. The EMT programme is linked to the acquisition of therapeu tic resistance in solid tumours 118 , and ABL signalling has recently been shown to be upregulated in chemo resistant breast tumours 123 . Thus, an intriguing possibil ity to be evaluated is whether ABL kinases are important for the induction and/or maintenance of EMT path ways that contribute to the acquisition of therapeutic resistance in diverse solid tumours.
Role of ABL kinases during invasion and metastasis.
Tumour progression and metastasis require the induc tion of an invasive programme that promotes dissemina tion into surrounding tissues by primary tumour cells, followed by intravasation, migration, extravasation and the formation of metastases at distant sites 124 . ABL kinases engage the actin polymerization machinery in response to growth factor and chemokine stimulation, as well as adhesion cues, and promote the formation of membrane protrusions, morphological changes, altered cell adhesion, and migration and invasion of diverse cell types 6, 37, 54, 70 . ABL kinases are required for cell motility and invasion induced by IGF1, EGF, serum and chemokines in breast, hepatocellular carcinoma and melanoma cells 8, 16, 33, 73, 84, 125 . One or both ABL kinases are required for invasion in several cancer cell lines, but ABL2 is preferentially required for the invasion of the MDAMB231 breast cancer cell line 84 . ABL kinases can regulate invasion by directly phosphorylating pro teins that are required for invasive behaviour, and also by regulating the expression of genes linked to inva sion and cell motility (FIG. 4) . ABL2 localizes to invado podia, where it is required for both matrix degradation and invasion in breast cancer cells 33, 73 . Knockdown of ABL2 decreases matrix degradation and invasion by MDAMB231 breast cancer cells, and ABL2 regulates the maturation of invadopodia by linking activation of the EGFR and SRC kinases to tyrosine phosphory lation of cortactin, which is required for ARP2/3 complex dependent actin polymerization 73 . In addition to cortactin, other actinregulatory proteins are targeted by ABL kinases at invadopodia (FIG. 4) . Among these is the Abl interactor 1 (ABI1) adaptor protein, a compo nent of the WAVE protein complex, which is required 54, 73, [126] [127] [128] 130 . ABL kinases regulate membrane type 1-matrix metalloproteinase (MT1-MMP) localization and activity 33 . ABL2 interacts with MT1-MMP promoting its phosphorylation (P), and extracellular matrix (ECM) degradation 33 . One or both ABL kinases are required for cancer cell invasion depending on the cellular context 16, 73 . ABL kinases also regulate cancer cell invasion by modulating expression of several MMPs and other genes involved in epidermal growth factor receptor (EGFR)-mediated invasion 16, 84 . for invadopodia formation, extracellular matrix deg radation and induction of matrix metalloproteinase 9 (MMP9) expression in MDAMB231 breast can cer cells 126 . ABL kinases also regulate the activity of MMPs during invadopodia maturation (FIG. 4) . Active ABL2 interacts with and promotes the phosphory lation of membrane type 1matrix metalloproteinase (MT1MMP; also known as MMP14) and is required for its localization and function at invadopodia 33 . Both ABL1 and ABL2 kinases are required for mela noma cell invasion by regulating MMP expression through STAT3dependent and STAT3independent pathways 16 (FIG. 4) . Other potential targets of ABL kinases at invadopodia include the NWASP (also known as WASL) actinregulatory protein, which is required for ARP2/3mediated actin polymerization at invado podia, and which is phosphorylated by ABL kinases [127] [128] [129] . Recently, HEF1 (also known as NEDD9) was identified as a direct substrate and binding part ner of the ABL kinases in T cells 54 . HEF1 also regulates cancer cell invasion, and ABLmediated phosphoryla tion of HEF1 may be required for promoting invasive behaviour, as observed during chemokineinduced T cell migration 130 . Consistent with its ability to posi tively regulate invadopodia formation and function, knockdown of ABL2 decreased cancer cell invasion and intravasation following implantation of MDAMB231 cells in the mammary fat pad 84 .
Pharmacological inhibition of ABL in cancer
To date, there are five approved ABL inhibitors for the treatment of BCR-ABL1 + CML
. The pharma cology and clinical data of these drugs have recently been reviewed 131 . Although imatinib has proved remarkably successful for the treatment of CML, par ticularly for patients in chronic phase, up to onethird of patients will require alternative therapies 132 . The effectiveness of imatinib decreases during the acute and blast stages of CML. Imatinib resistance may result from the development of mutations in BCR-ABL1 that alter drug binding, including the T315I gatekeeper mutation. Other ATPcompetitive inhibitors, such as nilotinib, dasatinib and bosutinib are also ineffective against the T315I mutant form of BCR-ABL1 (REF. 131 ).
Newer allosteric inhibitors have been tested in preclini cal models of resistance; among these are the GNF2 and GNF5 allosteric inhibitors that target the myristate pocket of ABL kinases (FIG. 1c) . Combining GNF5 with imatinib or nilotinib prolonged the survival of mice with imatinibresistant BCR-ABL1 T315Iinduced leukaemia 56 . Another type of allosteric inhibitor, an engineered ABL1 SH2binding fibronectin type III monobody, blocked the intramolecular interaction between the SH2 and kinase domains of BCR-ABL1, inhibited kinase activity in vitro and in vivo, impaired leukaemogenesis in mice, and increased the sensitiv ity of imatinibresistant BCR-ABL1 mutants to TKI therapies 133 . Thus, the combined use of allosteric and ATPcompetitive inhibitors may represent an effec tive strategy to overcome resistance to either type of compound alone.
Use of ABL kinase inhibitors for solid tumours: past and future. In contrast to the success of TKI therapies for the treatment of BCR-ABL1induced leukaemias, the use of the ATPcompetitive inhibitors imatinib, nilotinib and dasatinib has not achieved similar success for the treatment of solid tumours (reviewed in REFS 134, 135) . The variable clinical responses to these TKIs may reflect the heterogeneous nature of solid tumours, which often have acquired mutations in multiple tumourpromoting path ways. In addition, recent work has shown that signal ling networks can be rewired in response to treatment with single kinase inhibitors 136, 137 , which may underlie poor responses to treatment. Another mechanism that underlies the poor response to TKI therapy in some solid tumours and chemoresistant leukaemias is the targeting of alternative pathways, resulting in the para doxical activation of proliferative pathways. Treatment with imatinib, nilotinib and dasatinib can activate BRAF-CRAF (also known as RAF1) complexes in cells that express active RAS, which leads to enhanced acti vation of the MEK-ERK pathway in diverse cancer cell lines, including melanoma, lung, colorectal and pan creatic carcinoma, as well as BCR-ABL1 TKIresistant leukaemic cells 76 . The paradoxical MEK-ERK activation by these TKIs is reminiscent of the increased MEK-ERK pathway activation that is induced by vemurafenib, a BRAF inhibitor, in cancer cells expressing active RAS, which was reported to promote cell proliferation in soft agar and to accelerate cutaneous squamous cell tumours in mouse models and patients 138 . At the molecular level, whereas imatinib, nilotinib and dasatinib promote the formation of BRAF-CRAF complexes in cells with acti vated RAS, these TKIs are weak RAF inhibitors in vitro 76 . Therefore, the indiscriminate use of imatinib, nilotinib, dasatinib and other ABLtargeted ATPcompetitive TKIs is not recommended; rather, screening tumours for ABL amplification, enhanced expression and hyper activation, as well as coexpression of other mutations that are associated with poor response to specific TKIs, is cru cial for identifying those tumours that may benefit from therapies with selective ABL TKIs.
Notably, in contrast to the ABLtargeted ATP competitive TKIs, the ABL allosteric inhibitor GNF2 does not inhibit BRAF activity in vitro and fails to induce the formation of BRAF-CRAF dimers; thus, treatment with this compound does not elicit paradoxical activation of the MEK-ERK pathway 76 . Development of additional selective ABL TKIs and further mechanistic understand ing of the signalling networks disrupted in response to distinct ABL TKIs, may better inform the selection of therapies that can be used in combination with ABL inhibitors. Thus, tumours with ABL2 genomic amplifi cation and/or robust kinase activity (as detected by high levels of phosphorylated CRKL) might be predicted to be good candidates for TKIs that are selective for ABL kinases (and that do not target BRAF or other kinases that may induce paradoxical activation of MEK-ERK and other tumourpromoting pathways). Additionally, devel oping an ABL signature (genomic, transcriptional or phosphoproteomic) might be crucial to identify subsets of patients to rationally test the effects of these inhibitors.
Aromatase inhibitors
Drugs that block aromatase, the enzyme that converts androgens to oestrogens; used to treat oestrogen receptor + patients with breast cancer by decreasing circulating levels of oestrogenic compounds.
One interesting possibility for the future of ABL TKIs in cancer therapy may lie in overcoming resistance to chemotherapies. Enhanced expression of ABL1 signal ling networks was recently detected in endocrineresistant breast cancer 123 . The PDGFR-ABL1 pathway was identi fied as the top adaptive pathway that is characteristic of oestrogen receptor (ER)positive breast cancers that have acquired resistance to therapy with aromatase inhibitors. Activation of the PDGFR-ABL1 pathway was linked to longterm oestrogen deprivation in MCF7 breast cancer cells, and was associated with decreased antiproliferative response to aromatase inhibitor treatment in primary ERpositive breast carcinomas 123, 139 . Moreover, treat ment of these cells with nilotinib (which inhibits both PDGFR and ABL1), suppressed ERmediated transcrip tion by destabilizing ER. This finding is consistent with reports that ABL1 regulates ERαmediated transcription by inducing phosphorylation and stabilization of ERα 140 and that silencing ABL1 in ERpositive breast cancer cells sensitized these cells to tamoxifen treatment 141 . Treatment of breast cancer cells with imatinib has been shown to sen sitize these cells to certain drugs such as 5fluorouracil, cisplatin and vinorelbine 142, 143 . Furthermore, imatinib treatment or ABL1 depletion was shown to restore sen sitivity to the EGFR and ERBB2 inhibitor lapatinib in breast cancer cells that had acquired lapatinib resist ance 144 . Future studies are warranted to define how ABL1 inhibition sensitizes cancer cells to chemotherapies and whether such an approach may improve the effectiveness of chemotherapy in vivo.
Conclusions and perspectives
Although the ABL1 kinase was first linked to the induc tion of human leukaemia almost three decades ago 2 , a role for ABL family kinases in the progression of solid tumours has only recently been recognized. Over the past decade the use of imatinib, dasatinib and nilotinib to treat patients with BCR-ABL1positive leukaemias provided the best example for the successful use of TKItargeted therapy. However, it is clear that the use of these drugs as monotherapies is inadequate for the treatment of solid tumours owing to the complexity of mutations even in earlystage tumours, and the poten tial for inappropriate activation (rather than inhibition) of proliferative pathways by some TKIs with multi ple protein targets. Ongoing preclinical and future clinical studies are expected to evaluate whether the treatment of patients with tumours with ABL amplifi cation, enhanced expression and hyperactivation could benefit from therapies with ABLselective TKIs. The identification of new allosteric inhibitors with greater specificity against ABL family kinases may allow for the evaluation of the effectiveness of targeting these kinases in the treatment of solid tumours with hyper active ABL kinases, and whether antiABL therapies display greater effectiveness at specific tumour stages. Recent findings suggest that ABL1 and ABL2 may regulate overlapping, as well as distinct, cellular pro cesses in various cell types, and may differentially con tribute to tumour progression. Future studies will be required to evaluate unique roles for the ABL kinases not only in selected solid tumours, but also in cells in the tumour microenvironment. ABL kinases regulate diverse signalling pathways in fibroblasts, macrophages and T cells 34, 54, 70, 100, 145, 146 . These cell types are known to contribute to tumour progression and metastasis in various cancers [147] [148] [149] , and a role for ABL kinases in tumourpromoting pathways in distinct cell types in the microenvironment should be an area of active enquiry. Exciting research over the next few years is expected to evaluate the contribution of ABL kinases to distinct tumour types and to establish whether these kinases prove to be useful targets for the treatment of multiple solid tumour types.
